JAK1 and Alzheimer disease: In conclusion, the results obtained in the study reveal upregulation of IL-32 in AD increases JAK1 expression and thus activates its downstream signaling pathway, thereby promoting the expression of miR-155, which facilitates the development of AD (Fig. 7).